PROVIGIL 200 mg
C10953/3045/CM/US
Phase 3 small_molecule completed
Quick answer
PROVIGIL 200 mg for Chronic Shift Work Sleep Disorder is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Indication
- Chronic Shift Work Sleep Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed